Definition and scope
Alcohol has dose-, pattern-, duration-, sex-, and genetically influenced effects on the cardiovascular system. Acute exposure produces transient haemodynamic and myocardial effects, whereas sustained heavy consumption is associated with hypertension, coronary artery disease, arrhythmias, heart failure and alcohol-related cardiomyopathy.
The cardiovascular implications of lower alcohol intake remain controversial. Epidemiological studies have often described a J-shaped association between consumption and cardiovascular outcomes, with apparently lower overall cardiovascular risk around one drink daily. However, more recent analyses question whether this reflects true biological protection. Potentially favourable associations with myocardial infarction may coexist with adverse effects on stroke, heart failure, cardiovascular mortality and atrial fibrillation. Consequently, alcohol should not be initiated as a cardiovascular preventive strategy.
A drink-equivalent contains approximately 12–14 g of ethanol. Representative quantities are a 12-ounce regular beer containing approximately 5% alcohol, 5 fluid ounces of wine containing approximately 12% alcohol, or 1.5 fluid ounces of 40% distilled spirits. Habitual heavy consumption is defined in the source material as at least eight drinks weekly in females or at least 15 drinks weekly in males, or binge drinking in either sex. Other definitions of unhealthy drinking include at least two drinks daily in women or three in men, or at least four drinks for women or five for men on one occasion.
Pharmacokinetics and pathophysiology
Approximately 95% of ingested ethanol undergoes hepatic metabolism. Alcohol dehydrogenase converts ethanol to acetaldehyde, which is subsequently converted by aldehyde dehydrogenase to acetate. The remaining fraction is excreted unchanged in urine, perspiration and exhaled breath. Blood alcohol concentration generally peaks 10–60 minutes after ingestion. Elimination follows zero-order kinetics at low to moderate concentrations and first-order kinetics at higher concentrations.
Ethanol is water soluble and readily crosses cell membranes, allowing distribution throughout water-containing tissues, including the myocardium. Its effects therefore depend not only on dose but also on exposure pattern, duration, sex and genetic predisposition.
Acute cardiovascular effects
Acute ethanol exposure has a negative inotropic effect and promotes peripheral vasodilation through reduced systemic vascular resistance. The resulting mild reduction in blood pressure is often accompanied by a compensatory rise in cardiac output. Although these changes are usually of limited clinical importance in otherwise healthy individuals, they may be clinically relevant in established cardiac disease. Alcohol also increases the rise in myocardial oxygen consumption associated with exercise.
Chronic myocardial injury
Long-term heavy consumption can produce a cardiomyopathy, although the exact exposure threshold and duration required are not established. The source material identifies chronic intake of approximately 60 g daily in males and 40 g daily in females as capable of causing cardiomyopathy.
Several mechanisms contribute:
Direct toxic effects on cardiomyocytes
Disruption of intracellular signalling and protein synthesis
Electrical channelopathies
Oxidative stress
Cellular apoptosis and necrosis
Progressive structural remodelling
Alcohol-associated hypertension and atherosclerotic coronary disease
In patients with heavy alcohol use, left ventricular dilation may precede the development of increased left ventricular hypertrophy and mass. Initially, myocardial abnormalities may be subclinical. Progressive dilation can subsequently impair left ventricular ejection fraction. Enlargement of the left ventricle predisposes to atrial and ventricular arrhythmias.
In advanced alcohol-related cardiomyopathy, dilation may involve all four cardiac chambers. Associated findings can include left ventricular hypocontractility, heart failure, unexplained arrhythmias, mural thrombi and mitral regurgitation.
Vascular and coronary effects
Heavy alcohol consumption promotes atherosclerotic disease in coronary, peripheral and cerebral vessels. It is also associated with systemic hypertension. Consumption of three or more drinks daily produces a dose-dependent increase in blood pressure; this may return to normal within weeks of abstinence.
The relationship between alcohol and coronary artery disease is complex. Lower or moderate intake has been associated in some studies with reduced inflammation, increased high-density lipoprotein cholesterol, reduced low-density lipoprotein cholesterol and potentially favourable effects on lipoprotein(a). Alcohol may also influence ischaemic preconditioning and attenuate some cellular consequences of ischaemia–reperfusion injury. Conversely, higher doses may increase triglycerides and inflammatory markers and are associated with hypertension, tobacco use and other coronary risk factors. These opposing effects make a causal protective effect of low-dose alcohol uncertain.
Arrhythmogenesis
Alcohol can alter electrical channel function and promote atrial and ventricular arrhythmias. Heavy drinking may provoke paroxysmal tachycardia even in individuals without other evidence of structural heart disease. This transient syndrome is commonly termed “holiday heart.”
Alcohol consumption is also associated with atrial fibrillation. The relationship may extend across the consumption range, and recent evidence questions whether even low-to-moderate intake is free of atrial fibrillation risk. In established alcohol-related cardiomyopathy, chamber dilation further increases arrhythmic susceptibility.
Haemostatic effects
The source material describes alcohol-related platelet activation through increased inositol 1,4,5-trisphosphate and intracellular calcium, with rebound thrombocytosis. Increased plasminogen activator inhibitor-1 may impair fibrinolysis and thereby increase thrombotic potential. In a dilated, poorly contracting heart, these effects may compound the risk associated with mural thrombus formation.
Clinical presentation and symptoms
Clinical manifestations range from transient, self-limited haemodynamic or rhythm disturbances to progressive heart failure and dilated cardiomyopathy.
Acute presentations
Acute or episodic heavy drinking may be followed by:
Palpitations
Paroxysmal tachycardia
Atrial arrhythmias, including atrial fibrillation
Ventricular arrhythmias
A mild fall in blood pressure
Symptoms related to impaired exercise tolerance when underlying cardiac disease is present
Chronic presentations
Alcohol-related cardiomyopathy may present with:
Unexplained atrial or ventricular arrhythmias
Progressive dyspnoea related to heart failure
Reduced exercise capacity
Clinical evidence of low contractility
Peripheral congestion
Symptoms caused by mitral regurgitation
Thromboembolic manifestations from mural thrombi
The source material does not provide a detailed symptom-based classification of heart failure or a specific symptom profile distinguishing alcohol-related cardiomyopathy from other dilated cardiomyopathies.
Associated cardiovascular disease
Heavy alcohol use may coexist with:
Hypertension
Coronary artery disease
Myocardial infarction
Cerebrovascular disease
Peripheral arterial atherosclerosis
The association between alcohol and coronary disease is not uniform across studies, and cardiovascular assessment should therefore consider alcohol exposure alongside conventional risk factors, including hypertension, diabetes, obesity, dyslipidaemia and smoking.
Evaluation and physical examination
Alcohol history
A cardiovascular assessment should document:
Quantity consumed
Frequency and duration of consumption
Binge-pattern episodes
Recent heavy intake
Temporal association between drinking and palpitations or other symptoms
Previous periods of abstinence and any cardiovascular improvement during abstinence
Coexisting tobacco use and other coronary risk factors
Concurrent medications and relevant comorbidities
Pregnancy status where applicable
Family history of alcoholism
The history should also establish prior coronary disease, myocardial infarction, revascularisation, arrhythmia, syncope or presyncope, cerebrovascular disease and heart failure.
Cardiovascular examination
Examination should assess for:
Blood pressure elevation
Signs of volume overload or heart failure
Arrhythmia or tachycardia
Evidence of chamber dilation or impaired ventricular function
Mitral regurgitation
Peripheral manifestations of thromboembolism where clinically suspected
The provided material does not specify a complete cardiovascular examination protocol or characteristic physical signs uniquely diagnostic of alcohol-related cardiomyopathy.
Because heavy alcohol use frequently accompanies alcohol-associated liver disease, examination may also reveal systemic findings relevant to cardiovascular management, including oedema, ascites, hepatosplenomegaly, jaundice, muscle wasting, spider angiomas, palmar erythema, gynecomastia or testicular atrophy. These findings may influence assessment of comorbidity and treatment tolerance.
Diagnostics
Electrocardiography
The source material establishes that alcohol may cause atrial and ventricular arrhythmias, paroxysmal tachycardia and electrical channelopathies. Accordingly, electrocardiographic assessment is relevant when palpitations, syncope, presyncope, unexplained tachycardia or suspected cardiomyopathy is present.
However, the source material does not describe specific ECG patterns, conduction abnormalities, QT measurements or diagnostic criteria for alcohol-related cardiomyopathy.
Cardiac imaging
The principal structural abnormalities described are:
Left ventricular dilation
Subsequent increases in left ventricular hypertrophy and mass
Reduced left ventricular ejection fraction with progression
Dilation of all four cardiac chambers in advanced disease
Hypocontractility
Possible mural thrombi
Associated mitral regurgitation
Cardiac imaging is therefore relevant for documenting chamber dimensions, ventricular contractility, ejection fraction, valvular regurgitation and intracardiac thrombus. The source material does not specify a preferred imaging modality or provide quantitative imaging thresholds.
Coronary and vascular assessment
Heavy alcohol intake is associated with coronary, peripheral and cerebral atherosclerosis. Evaluation should therefore be guided by symptoms and cardiovascular risk profile. The material does not provide specific indications for stress testing, coronary computed tomography, invasive angiography or vascular imaging.
Electrophysiology
The provided material does not discuss electrophysiological study, catheter ablation or other invasive electrophysiological strategies.
Biomarkers and laboratory findings
No cardiac biomarker pattern specific to alcohol-related cardiovascular disease is provided. The source material does, however, identify several laboratory and metabolic effects relevant to cardiovascular risk:
Increased high-density lipoprotein cholesterol and reduced low-density lipoprotein cholesterol have been reported with some alcohol exposure patterns.
High-dose intake may increase triglycerides.
Heavy alcohol use may increase inflammatory markers.
Alcohol-associated hypertension may improve after abstinence.
In patients with concomitant alcohol-associated liver disease, laboratory abnormalities may include anaemia, thrombocytopenia, elevated aminotransferases, hyperbilirubinaemia and prolonged prothrombin time. Aspartate aminotransferase is typically higher than alanine aminotransferase, often in an approximately 2:1 relationship, and aminotransferase values are usually below 400 IU/mL. These abnormalities are not diagnostic of alcohol-related cardiomyopathy but may affect cardiovascular assessment and medication management.
Early compensated alcohol-associated cirrhosis may have entirely normal laboratory results. Consequently, normal routine tests do not exclude clinically important alcohol-related disease.
Treatment and management
Alcohol reduction and abstinence
The central intervention for alcohol-related cardiovascular disease is reduction or cessation of alcohol consumption. Patients drinking heavily should be counselled to limit intake, and treatment should address the alcohol-use disorder itself.
Abstinence may:
Improve blood pressure, with normalization potentially occurring within weeks
Improve clinical status in alcohol-related cardiomyopathy
Improve left ventricular ejection fraction in some patients
Reduce ongoing direct myocardial toxicity
Address a major modifiable driver of disease progression
The source material does not provide a pharmacological regimen for alcohol-use disorder, a medically supervised withdrawal protocol or specific referral pathways.
Moderate alcohol consumption should not be initiated for cardiovascular prevention. Preventive priorities include dietary measures, physical activity, lipid control, blood-pressure control and smoking cessation.
Management of cardiomyopathy and heart failure
Patients with alcohol-related cardiomyopathy should receive guideline-directed medical and device therapies appropriate to their cardiomyopathy and heart-failure status. The supplied material does not specify the individual drug classes, doses, device indications or treatment sequencing.
Management should also address:
Ventricular function and chamber dilation
Atrial and ventricular arrhythmias
Mitral regurgitation
Intracardiac mural thrombi
Coexisting coronary artery disease
Hypertension
Thromboembolic risk
Liver disease and its effects on treatment safety
Arrhythmia management
Acute management should be directed by the documented rhythm and haemodynamic status. Because alcohol may precipitate paroxysmal tachycardia, atrial arrhythmias and ventricular arrhythmias, rhythm assessment is important after episodes of heavy drinking and in patients with cardiomyopathy.
The source material does not provide antiarrhythmic drug doses, rate-control regimens, anticoagulation protocols, cardioversion criteria or ablation recommendations.
Hypertension
Consumption of three or more drinks daily is associated with a dose-dependent increase in blood pressure. Alcohol reduction or abstinence is therefore an important component of blood-pressure management. The material does not provide antihypertensive drug choices or doses.
Coronary risk management
Alcohol should not be prescribed or recommended to prevent coronary disease. Management should instead focus on established risk-factor interventions, including:
Lipid control
Blood-pressure control
Smoking cessation
Physical activity
Dietary improvement
Appropriate evaluation of symptoms suggestive of coronary disease
The source material does not provide drug doses for lipid-lowering therapy, antiplatelet therapy or anti-ischaemic treatment.
Drugs and practical prescribing considerations
The supplied material does not specify cardiovascular drug names, doses or dose-adjustment protocols for patients with alcohol-related cardiovascular disease.
Prescribing should nevertheless account for the frequent coexistence of alcohol-associated liver disease, which may involve thrombocytopenia, impaired coagulation, hyperbilirubinaemia and abnormal aminotransferases. The material does not define how these abnormalities should alter individual cardiovascular prescriptions.
Guideline recommendations
The principal recommendations supported by the source material are:
Moderate alcohol consumption should not be initiated as a cardiovascular preventive intervention.
Patients with heavy alcohol use should be counselled to reduce intake.
Recommendations should be individualized according to comorbid disease, coronary risk factors, concurrent medications, pregnancy and family history of alcoholism.
Cardiovascular prevention should emphasize diet, physical activity, lipid control, blood-pressure control and smoking cessation.
Alcohol use at moderate or higher doses is associated with hypertension, atrial arrhythmias and cardiomyopathy.
In alcohol-related cardiomyopathy, treatment should include focused management of alcohol dependence together with guideline-directed medical and device therapy for cardiomyopathy.
The possibility of alcohol-related disease should be considered when arrhythmias, heart failure, ventricular impairment or cardiac dilation occur in the setting of substantial alcohol exposure.
Prognosis and follow-up
Prognosis depends strongly on continued alcohol exposure, the degree of myocardial dysfunction and the presence of associated coronary or systemic disease.
Persistent consumption of large amounts of ethanol in patients with non-ischaemic cardiomyopathy is associated with an annual mortality of approximately 10%. Mortality is higher among those who continue drinking; one study cited in the source material reported a median survival of 50% at four years. The reported risk of sudden cardiac death in a cohort with autopsy-proven alcohol-related cardiomyopathy was 5%.
Abstinence can lead to improvement in clinical status and left ventricular ejection fraction in some patients, although recovery is not universal. Follow-up should therefore evaluate:
Sustained abstinence or reduction in alcohol exposure
Symptoms and functional status
Blood pressure
Arrhythmia recurrence
Ventricular function and chamber dimensions
Mitral regurgitation
Intracardiac thrombus where previously identified
Coexisting coronary disease
Liver dysfunction and its implications for treatment
The source material does not define a specific follow-up interval or imaging schedule. Continued cardiovascular surveillance is particularly important when drinking persists, ventricular dysfunction is established or arrhythmias have occurred.
